<DOC>
	<DOCNO>NCT02808897</DOCNO>
	<brief_summary>The purpose study assess effectiveness PleuraFlow® Active Clearance Technology® ( ACT ) reduce rate postoperative atrial fibrillation ( POAF ) among post cardiac surgery patient evaluate impact ACT complication , retain blood syndrome ( RBS ) , composite endpoint include re-exploration bleeding tamponade , intervention hemothorax , pericardial pleural effusion .</brief_summary>
	<brief_title>The Effect Chest Tubes Using Active Clearance Technology® Incidence Postoperative Atrial Fibrillation</brief_title>
	<detailed_description>Data collect stored department surgery Montreal Heart Institute . Only principal investigator study coordinator access database . The primary analysis intention-to-treat ( ITT ) analysis compare POAF rate PleuraFlow® group POAF rate control group . Based finding institutional clinical database Montreal Heart Institute , local incidence POAF cardiac surgery approximately 25 % ( control group ) . The proportion ACT group ( treatment group ) assume 0,2500 null hypothesis 0,1500 alternative hypothesis . Group sample size 254 group achieve 80 % power detect difference group proportion 0,1000 use Chi-Square test significance level 0.0476 . This significance level compute use O'Brien-Fleming method account interim analysis plan 300 randomized subject complete 30-day follow-up . POAF intervention treat RBS rate categorical event rate compare use chi-square test . Multiple logistic regression adjust potential confounding factor also use . Odds ratio associate 95 % confidence interval compute descriptive purpose . Goodness fit check use Hosmer-Lemeshow statistic . Quantitative endpoint investigate use Student t-tests . Analysis covariance may also use account potential confounding factor . Nonparametric test data transformation may use quantitative endpoint normally distribute . Correlations associate 95 % confidence interval compute descriptive purpose . An interim analysis conduct first 300 randomized subject complete 30-day follow-up . The primary endpoint ( POAF rate ) compare PleuraFlow® group control group use chi-square test . The significance level test 0.0076 , compute use O'Brien-Fleming method . If p-value chi-square test bound interim analysis , study stop efficacy . Otherwise , study continue plan 508 patient . As result interim look , final analysis primary endpoint would require p &lt; 0.0476 declare statistically significant . Analysis secondary endpoint outcomes conduct 0.05 significance level .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pericardial Effusion</mesh_term>
	<mesh_term>Hemothorax</mesh_term>
	<mesh_term>Cardiac Tamponade</mesh_term>
	<criteria>1 . Admission coronary artery bypass graft ( CABG ) , valve replacement valve repair surgery , combination surgery ; 2 . Surgical procedure ( ) ascend aorta and/or aortic arch require deep hypothermic arrest ( deep hypothermic arrest define &lt; 14° C ) ; 3 . Must sinus rhythm ( SR ) minimum 30 day prior index surgery start index surgery . No patient history atrial fibrillation . 4 . Sign institutional review board/institutional ethic committee approve informed consent form nature study explain questions/concern address . 1 . Admitted surgical treatment arrhythmia Atrial fibrillation history ; 2 . Admitted cardiac surgery require implantation/explantation Ventricular Assist Device ( VAD ) heart transplant ; 3 . Admitted Transcatheter aortic valve replacement ( TAVR ) ; 4 . Cardiac surgical procedure require deep hypothermic arrest ( define ) ; 5 . New active endocarditis myocarditis adequately control medication and/or require surgical intervention ; 6 . Documented inherited bleeding disorder ( ) ; 7 . History known allergy device material .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chest tube</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Thoracic surgery</keyword>
	<keyword>Critical care</keyword>
</DOC>